Research News Update from Steve

"Intrathecal Cyclosporin is one of the new protocols being developed for the treatment of ALS that I referred to in our last newsletter. While only in Phase 2 (dosage/efficacy), having succeeded in Phase 1 (safety), the intrathecal usage of Cyclosporin is, in my opinion, one of the leading opportunities to have come to the forefront in the past several years. Whereas Cyclosporin has been considered for ALS since the early 1980's and was trialed by Dr Stanley Appel in 1988 as an oral medication, it is only since its use as an intrathecally-delivered medication (injected into the spinal cord) that its promise seems more relevant. I intend to meet with Maas Biolab in December at their facility in Albuquerque to gain more information, having first become interested in their approach to Cyclosporin A through intrathecal injection (Mitogard) when meeting with them at the MNDA Symposium in Toronto in November 2007."

We hope you find this information useful and that you visit ALS WORLDWIDE frequently.

Barb and Steve Byer
September 7, 2